Swiss pharmaceutical company Novartis has observed in a clinical trial the superiority of its Scemblix over the current standard of care for patients diagnosed with Philadelphia chromosome-positive chronic myeloid leukaemia after 48 weeks.
This content was published on
2 minutes
Keystone-SDA
Español
es
Novartis avanza con un fármaco contra la leucemia mieloide
The currently experimental treatment has demonstrated a significant response rate both statistically and clinically, thus meeting the two primary evaluation criteria set for the Asc4first program, assures the Basel group in a press release, without time to detail the extent of these advantages.
Scemblix (asciminib) also has a more favorable safety profile than the cocktail of imatinib, nilotinib, dasatinib and bosutinib (TKIs), generally administered to these patients.
Novartis plans to detail the results obtained at an upcoming medical conference. In the meantime, the laboratory points out that more than 60% of people with Philadelphia chromosome-positive chronic myelogenous leukaemia fail to show a molecular response to TKIs after one year and that the side effects of this type of treatment burden lead a quarter of patients to abandon treatment before five years.
The Asc4first program continues, with a new update planned when data on 96 weeks of treatment is available.
More
More
Three Swiss companies among the 100 most valuable in the world
This content was published on
Three Swiss companies have once again made it into the top 100 most valuable listed companies in the world.
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Workplace Switzerland
What lies ahead for Switzerland: an economic outlook for 2025
New Year’s speech: President Keller-Sutter praises Swiss modesty
This content was published on
The Swiss president for 2025, Karin Keller-Sutter, has underlined the importance of compromise and modesty in Swiss politics in her New Year’s address to the nation.
Lindt wins ‘chocolate ball’ legal case against Aldi
This content was published on
Chocolate manufacturer Lindt & Sprüngli has won a legal case against the retailer Aldi Suisse for infringing the trademark rights of its Lindor chocolate balls.
Campaigners want Swiss central bank to hold bitcoin in reserves
This content was published on
Campaigners have launched a people's initiative to oblige the Swiss National Bank (SNB) to hold part of its reserves in bitcoin.
Switzerland welcomes 2025 with fireworks and ice plunges
This content was published on
Fireworks lit up the skies in Switzerland to celebrate New Year's Eve. Some people welcomed the new year by plunging into lakes in freezing temperatures.
This content was published on
After the emergency landing of a SWISS aircraft in Graz last week, inquiries have detected a “previously unknown fault pattern” in an engine.
Appeals filed against new Rottweiler ban in Zurich
This content was published on
Authorities in Zurich say they have received several appeals against a new ban on Rottweilers starting on January 1, 2025.
Record number of start-ups founded in Switzerland in 2024
This content was published on
Almost 53,000 start-ups were registered in 2024, up from 51,500 the previous year, the Institut für Jungunternehmen (IFJ) said on Tuesday.
Russian ambassador praises Swiss openness for dialogue
This content was published on
Sergei Garmonin says Swiss willingness to keep communications channels open is “noticeably better than in a number of other Western countries”.
Swiss researchers help to pinpoint 200-year-old volcanic eruption
This content was published on
Scientists have finally discovered which volcano was behind an 1831 eruption that impacted climate and crops across the world.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis withdraws patent claim on leukaemia treatment
This content was published on
The Swiss NGO Public Eye is claiming victory in the European Patent OfficeExternal link battle, but Novartis says the patent in question was only one of several it has in place on the (CAR)-T cell therapy treatment it had developed together with the University of Pennsylvania. Public Eye says the therapy costs CHF370,000 ($376,000), which…
Sandoz CEO: Switzerland could save millions on medicines
This content was published on
Sandoz chief executive Richard Saynor says Switzerland could save millions on medicine if it made greater use of generic medicine.
This content was published on
Pressure groups Public Eye and Médecins du Monde have filed their objection to the European patent office in Munich. They claim that Kymriah was not invented by Novartis because the research behind the drug was carried out by public institutions. The medicament, which is used to treat leukaemia and lymph gland cancer on patients who have…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.